AbbVie Announces Positive Phase III Results
"While AbbVie is widely expected to be the second entrant to the soon-to-explode market for hepatitis C cocktail drugs after standard-bearer Gilead Sciences, promising data from latecomer Merck have analysts relegating the Illinois company to third place despite some excellent late-stage results.
At this week's International Liver Congress in London, AbbVie is trumpeting stellar Phase III results from its three-drug combination, which posted 12-week cure rates upward of 96% in patients with hard-to-treat genotype 1 hep C and in those who've already failed to derive a benefit from previous treatment. The results, published in The New England Journal of Medicine, are part of AbbVie's expansive late-stage program in which it tracked more than 2,300 patients, and the data will support an application for FDA approval expected this quarter."
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2014 Infectious Diseases Society of America